Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases

Zhao Zhong Chong, Benjarat Changyaleket, Haoliang Xu, Randy O. Dull, David E. Schwartz

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.

Original languageEnglish (US)
Pages (from-to)1571-1596
Number of pages26
JournalCurrent medicinal chemistry
Volume23
Issue number15
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Biomarkers
Brain Injuries
Brain
Therapeutics
Cerebrovascular Disorders
Motor Neuron Disease
Calcium-Binding Proteins
1-Phosphatidylinositol 4-Kinase
Pathologic Processes
Mitogen-Activated Protein Kinases
Neurodegenerative diseases
Cell signaling
Neuroglia
Neurodegenerative Diseases
Cyclic AMP
Communicable Diseases
Schizophrenia
Diabetes Mellitus
Myocardial Infarction
Medical problems

Keywords

  • Biomarker
  • Diabetes
  • MAPK
  • Neurodegeneration
  • PI3K
  • RAGE
  • Stroke

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases. / Chong, Zhao Zhong; Changyaleket, Benjarat; Xu, Haoliang; Dull, Randy O.; Schwartz, David E.

In: Current medicinal chemistry, Vol. 23, No. 15, 01.05.2016, p. 1571-1596.

Research output: Contribution to journalArticle

Chong, ZZ, Changyaleket, B, Xu, H, Dull, RO & Schwartz, DE 2016, 'Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases', Current medicinal chemistry, vol. 23, no. 15, pp. 1571-1596.
Chong, Zhao Zhong ; Changyaleket, Benjarat ; Xu, Haoliang ; Dull, Randy O. ; Schwartz, David E. / Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases. In: Current medicinal chemistry. 2016 ; Vol. 23, No. 15. pp. 1571-1596.
@article{022efb5b7f374e759a4b6cc35c4199d7,
title = "Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases",
abstract = "The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.",
keywords = "Biomarker, Diabetes, MAPK, Neurodegeneration, PI3K, RAGE, Stroke",
author = "Chong, {Zhao Zhong} and Benjarat Changyaleket and Haoliang Xu and Dull, {Randy O.} and Schwartz, {David E.}",
year = "2016",
month = "5",
day = "1",
language = "English (US)",
volume = "23",
pages = "1571--1596",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases

AU - Chong, Zhao Zhong

AU - Changyaleket, Benjarat

AU - Xu, Haoliang

AU - Dull, Randy O.

AU - Schwartz, David E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.

AB - The calcium binding protein S100B has attracted great attention as a biomarker for a variety of diseases. S100B is mainly expressed in glial cells and functions through intracellular and extracellular signaling pathways. The biological roles of S100B have been closely associated with its concentrations and its physiological states. The released S100B can bind to the receptor of advanced glycation end products and induce the initiation of multiple cell signaling transductions. The regulation of S100B bioactivities has been suggested through phosphoinositide 3 kinase/Akt, p53, mitogen-activated protein kinases, transcriptional factors including nuclear factor-kappaB, and cyclic adenosine monophosphate. The levels of S100B in the blood may function to predict the progress or the prognosis of many kinds of diseases, such as cerebrovascular diseases, neurodegenerative diseases, motor neuron diseases, traumatic brain injury, schizophrenia, depression, diabetes mellitus, myocardial infarction, cancer, and infectious diseases. Given that the activity of S100B has been implicated in the pathological process of these diseases, S100B should not be simply regarded as a biomarker, it may also function as therapeutic target for these diseases. Further elucidation of the roles of S100B may formulate innovative therapeutic strategies for multiple diseases.

KW - Biomarker

KW - Diabetes

KW - MAPK

KW - Neurodegeneration

KW - PI3K

KW - RAGE

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=84973867518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973867518&partnerID=8YFLogxK

M3 - Article

C2 - 27048377

AN - SCOPUS:84973867518

VL - 23

SP - 1571

EP - 1596

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 15

ER -